PyKafka: Fast, Pythonic Kafka, at Last!

Related Stories

Days since last Rust Minecraft server

Tldx – CLI tool for fast domain name discovery

Show HN: Fast Random Library for C++17

biski64 – A fast and robust Java PRNG (~.47ns/call)

The Last 5-Speed Manual in the US Is Gone

Why is PS3 emulation so fast: RPCS3 optimizations explained [video]

💥 Introducing AtomixCore — An open-source forge for strange, fast, and rebellious software

tpde: A fast framework for writing baseline compiler back-ends in C++

A critical look at NetBSD’s installer

When was the last time the go authors addressed or talked about error handling proposals?

Teaching Program Verification in Dafny at Amazon (2023)

A Look Back at Recent Car Carrier Fires

Reddit sues Anthropic, alleging its bots accessed Reddit more than 100,000 times since last July

Personalities at Work • Dr. Brian Little [Old, but Gold!]

Antarctic Ice Sheet tipping in the last 800,000 years warns of future ice loss - Communications Earth & Environment

Swift at Apple: Migrating the Password Monitoring Service from Java

Just how bad are we at treating age-related diseases?

i have 700 hours ak spray sucks at 125m any tips also why do i shoot more accurate at 125m when i use silencer lol

Filmmakers Used 20 iPhones at Once to Shoot '28 Years Later'

Why DeepSeek is cheap at scale but expensive to run locally

Snowflake Finance VP Says Big Companies Migrate at a Glacial Pace

Unsold Cybertrucks Are Piling Up at a Decaying US Shopping Mall

Need Advice: Should I Take LLVM Engineer Internship at NVIDIA India?

Trump's gamble puts the dollar at risk as the reserve currency

Conformance checking at MongoDB: Testing that our code matches our TLA+ specs

Where in the world are babies at the lowest risk of dying?

Tinder revamp aimed at Gen Zers who 'don't have as much sex'

Reaching my first 100 users without money or audience (at 10K users now)

Largest punk archive to find new home at MTSU's Center for Popular Music

Glioblastoma (GBM), an aggressive and fast-growing brain cancer, became smaller after dual-target CAR T-cell therapy in nearly two-thirds of patients